Simvastatin reduces circulating oxysterol levels in men with hypercholesterolemia

Heraliyawala K Dias, Ivana Milic, Gregory Y.H. Lip, Maria Cristina Polidori, Andrew Devitt, Helen R Griffiths

Research output: Contribution to journalArticle

Abstract

Oxysterols (OHC) are biologically active cholesterol metabolites circulating in plasma that may be formed enzymatically (e.g. 24S-OHC, 25S-OHC and 27-OHC) or by autoxidative mechanisms (e.g. 7-ketocholesterol, 7β-OHC and 25S-OHC). Oxysterols are more soluble than cholesterol and are reported to exert inflammatory, cytoprotective and apoptotic effects according to concentration and species. Esterified oxysterols have been analysed in people with dementia and cardiovascular diseases although there is no consistent relationship between oxysterol esters and disease. However, oxysterol esters are held in lipoprotein core and may not relate to the concentration and activity of plasma free oxysterols. Methodological limitations have challenged the analysis of free oxysterols to date. We have developed a fast, sensitive and specific quantitative LC-MS/MS, multiple reaction monitoring (MRM) method to target five oxysterols in human plasma with analyte recoveries between 72-82 % and sensitivities between 5-135ng. A novel method was used to investigate the hypothesis that simvastatin may reduce the concentrations of specific plasma free oxysterols in hypercholesterolaemia. Twenty healthy male volunteers were recruited (aged 41-63 years); ten were asymptomatic with high plasma cholesterol >6.5mM and ten were healthy with normal plasma cholesterol (<6.5mM). Simvastatin (40mg/day) was prescribed to those with hypercholesterolaemia. Plasma samples were taken from both groups at baseline and after three months. Simvastatin reduced plasma cholesterol by ~35% (p<0.05) at the end of three months. Oxysterols generated by autoxidation but not enzymatically were elevated more than 100 fold in hypercholesterolaemic midlife men. Plasma oxysterols were restored to those of healthy controls after simvastatin intervention suggesting that autoxidation is either prevented by simvastatin directly or that autoxidation is less prevalent when plasma cholesterol concentrations are in the normal range.
Original languageEnglish
Pages (from-to)139-145
JournalRedox biology
Volume16
Early online date17 Feb 2018
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Simvastatin
Hypercholesterolemia
Plasmas
Cholesterol
Esters
Plasma (human)
Oxysterols
Metabolites
Lipoproteins
Dementia
Healthy Volunteers
Reference Values
Cardiovascular Diseases
Recovery
Monitoring

Bibliographical note

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0)

Keywords

  • hydroxycholesterol, mass spectrometry, statin, vascular disease, dementia

Cite this

Dias, Heraliyawala K ; Milic, Ivana ; Lip, Gregory Y.H. ; Polidori, Maria Cristina ; Devitt, Andrew ; Griffiths, Helen R. / Simvastatin reduces circulating oxysterol levels in men with hypercholesterolemia. In: Redox biology. 2018 ; Vol. 16. pp. 139-145.
@article{225ce5ef0bc64672bd14d6a82a1a0dd7,
title = "Simvastatin reduces circulating oxysterol levels in men with hypercholesterolemia",
abstract = "Oxysterols (OHC) are biologically active cholesterol metabolites circulating in plasma that may be formed enzymatically (e.g. 24S-OHC, 25S-OHC and 27-OHC) or by autoxidative mechanisms (e.g. 7-ketocholesterol, 7β-OHC and 25S-OHC). Oxysterols are more soluble than cholesterol and are reported to exert inflammatory, cytoprotective and apoptotic effects according to concentration and species. Esterified oxysterols have been analysed in people with dementia and cardiovascular diseases although there is no consistent relationship between oxysterol esters and disease. However, oxysterol esters are held in lipoprotein core and may not relate to the concentration and activity of plasma free oxysterols. Methodological limitations have challenged the analysis of free oxysterols to date. We have developed a fast, sensitive and specific quantitative LC-MS/MS, multiple reaction monitoring (MRM) method to target five oxysterols in human plasma with analyte recoveries between 72-82 {\%} and sensitivities between 5-135ng. A novel method was used to investigate the hypothesis that simvastatin may reduce the concentrations of specific plasma free oxysterols in hypercholesterolaemia. Twenty healthy male volunteers were recruited (aged 41-63 years); ten were asymptomatic with high plasma cholesterol >6.5mM and ten were healthy with normal plasma cholesterol (<6.5mM). Simvastatin (40mg/day) was prescribed to those with hypercholesterolaemia. Plasma samples were taken from both groups at baseline and after three months. Simvastatin reduced plasma cholesterol by ~35{\%} (p<0.05) at the end of three months. Oxysterols generated by autoxidation but not enzymatically were elevated more than 100 fold in hypercholesterolaemic midlife men. Plasma oxysterols were restored to those of healthy controls after simvastatin intervention suggesting that autoxidation is either prevented by simvastatin directly or that autoxidation is less prevalent when plasma cholesterol concentrations are in the normal range.",
keywords = "hydroxycholesterol, mass spectrometry, statin, vascular disease, dementia",
author = "Dias, {Heraliyawala K} and Ivana Milic and Lip, {Gregory Y.H.} and Polidori, {Maria Cristina} and Andrew Devitt and Griffiths, {Helen R}",
note = "{\circledC} 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0)",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.redox.2018.02.014",
language = "English",
volume = "16",
pages = "139--145",
journal = "Redox biology",
issn = "2213-2317",
publisher = "Elsevier",

}

Simvastatin reduces circulating oxysterol levels in men with hypercholesterolemia. / Dias, Heraliyawala K; Milic, Ivana; Lip, Gregory Y.H.; Polidori, Maria Cristina; Devitt, Andrew; Griffiths, Helen R.

In: Redox biology, Vol. 16, 01.06.2018, p. 139-145.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Simvastatin reduces circulating oxysterol levels in men with hypercholesterolemia

AU - Dias, Heraliyawala K

AU - Milic, Ivana

AU - Lip, Gregory Y.H.

AU - Polidori, Maria Cristina

AU - Devitt, Andrew

AU - Griffiths, Helen R

N1 - © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0)

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Oxysterols (OHC) are biologically active cholesterol metabolites circulating in plasma that may be formed enzymatically (e.g. 24S-OHC, 25S-OHC and 27-OHC) or by autoxidative mechanisms (e.g. 7-ketocholesterol, 7β-OHC and 25S-OHC). Oxysterols are more soluble than cholesterol and are reported to exert inflammatory, cytoprotective and apoptotic effects according to concentration and species. Esterified oxysterols have been analysed in people with dementia and cardiovascular diseases although there is no consistent relationship between oxysterol esters and disease. However, oxysterol esters are held in lipoprotein core and may not relate to the concentration and activity of plasma free oxysterols. Methodological limitations have challenged the analysis of free oxysterols to date. We have developed a fast, sensitive and specific quantitative LC-MS/MS, multiple reaction monitoring (MRM) method to target five oxysterols in human plasma with analyte recoveries between 72-82 % and sensitivities between 5-135ng. A novel method was used to investigate the hypothesis that simvastatin may reduce the concentrations of specific plasma free oxysterols in hypercholesterolaemia. Twenty healthy male volunteers were recruited (aged 41-63 years); ten were asymptomatic with high plasma cholesterol >6.5mM and ten were healthy with normal plasma cholesterol (<6.5mM). Simvastatin (40mg/day) was prescribed to those with hypercholesterolaemia. Plasma samples were taken from both groups at baseline and after three months. Simvastatin reduced plasma cholesterol by ~35% (p<0.05) at the end of three months. Oxysterols generated by autoxidation but not enzymatically were elevated more than 100 fold in hypercholesterolaemic midlife men. Plasma oxysterols were restored to those of healthy controls after simvastatin intervention suggesting that autoxidation is either prevented by simvastatin directly or that autoxidation is less prevalent when plasma cholesterol concentrations are in the normal range.

AB - Oxysterols (OHC) are biologically active cholesterol metabolites circulating in plasma that may be formed enzymatically (e.g. 24S-OHC, 25S-OHC and 27-OHC) or by autoxidative mechanisms (e.g. 7-ketocholesterol, 7β-OHC and 25S-OHC). Oxysterols are more soluble than cholesterol and are reported to exert inflammatory, cytoprotective and apoptotic effects according to concentration and species. Esterified oxysterols have been analysed in people with dementia and cardiovascular diseases although there is no consistent relationship between oxysterol esters and disease. However, oxysterol esters are held in lipoprotein core and may not relate to the concentration and activity of plasma free oxysterols. Methodological limitations have challenged the analysis of free oxysterols to date. We have developed a fast, sensitive and specific quantitative LC-MS/MS, multiple reaction monitoring (MRM) method to target five oxysterols in human plasma with analyte recoveries between 72-82 % and sensitivities between 5-135ng. A novel method was used to investigate the hypothesis that simvastatin may reduce the concentrations of specific plasma free oxysterols in hypercholesterolaemia. Twenty healthy male volunteers were recruited (aged 41-63 years); ten were asymptomatic with high plasma cholesterol >6.5mM and ten were healthy with normal plasma cholesterol (<6.5mM). Simvastatin (40mg/day) was prescribed to those with hypercholesterolaemia. Plasma samples were taken from both groups at baseline and after three months. Simvastatin reduced plasma cholesterol by ~35% (p<0.05) at the end of three months. Oxysterols generated by autoxidation but not enzymatically were elevated more than 100 fold in hypercholesterolaemic midlife men. Plasma oxysterols were restored to those of healthy controls after simvastatin intervention suggesting that autoxidation is either prevented by simvastatin directly or that autoxidation is less prevalent when plasma cholesterol concentrations are in the normal range.

KW - hydroxycholesterol, mass spectrometry, statin, vascular disease, dementia

UR - http://europepmc.org/abstract/med/29501047

UR - https://www.sciencedirect.com/science/article/pii/S2213231718300995?via%3Dihub

U2 - 10.1016/j.redox.2018.02.014

DO - 10.1016/j.redox.2018.02.014

M3 - Article

C2 - 29501047

VL - 16

SP - 139

EP - 145

JO - Redox biology

JF - Redox biology

SN - 2213-2317

ER -